$9.43
2.58% yesterday
Nasdaq, Dec 02, 10:12 pm CET
ISIN
US6821431029
Symbol
OMER

Omeros Corporation Stock price

$9.43
+2.26 31.52% 1M
+6.35 206.17% 6M
-0.45 4.55% YTD
-2.52 21.09% 1Y
+7.38 360.00% 3Y
-3.00 24.14% 5Y
-6.38 40.35% 10Y
+0.70 8.02% 20Y
Nasdaq, Closing price Tue, Dec 02 2025
-0.25 2.58%
ISIN
US6821431029
Symbol
OMER
Industry

Key metrics

Basic
Market capitalization
$668.6m
Enterprise Value
$980.9m
Net debt
$312.3m
Cash
$36.1m
Shares outstanding
70.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-65.9%
Return on Equity
86.0%
ROCE
-123.3%
ROIC
-
Debt/Equity
-1.6
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-128.4m | $-43.2m
EBIT
$-129.4m | $-135.8m
Net Income
$-121.2m | $-134.9m
Free Cash Flow
$-105.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
23.7% | 74.3%
EBIT
23.5% | 19.7%
Net Income
9.8% | 14.1%
Free Cash Flow
32.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.8
FCF per Share
$-1.5
Short interest
19.5%
Employees
202
Rev per Employee
$0.0
Show more

Is Omeros Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,085 stocks worldwide.

Omeros Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Omeros Corporation forecast:

8x Buy
73%
3x Hold
27%

Analyst Opinions

11 Analysts have issued a Omeros Corporation forecast:

Buy
73%
Hold
27%

Financial data from Omeros Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 44 44
8% 8%
-
- Research and Development Expense 85 85
32% 32%
-
-128 -128
24% 24%
-
- Depreciation and Amortization 1.03 1.03
21% 21%
-
EBIT (Operating Income) EBIT -129 -129
23% 23%
-
Net Profit -121 -121
10% 10%
-

In millions USD.

Don't miss a Thing! We will send you all news about Omeros Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Omeros Corporation Stock News

Neutral
Business Wire
2 days ago
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart (formerly OMS906). Zaltenibart is a first-in-class, late-stage clinical humanized monoclonal antibody targeting MASP-3 – the most upstream and key activator of the alternative pathway of the complem...
Neutral
Seeking Alpha
16 days ago
Omeros Corporation ( OMER ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Gregory Demopulos - Co-Founder, Chairman, CEO & President David Borges - VP of Finance, Chief Accounting Officer & Treasurer Nadia Dac - VP & Chief Commercial Officer Conference Call Participants Jennifer Williams Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Stephen Brozak - WBB...
Neutral
Business Wire
20 days ago
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2025, which include: Net loss for the third quarter of 2025 was $30.9 million, or $0.47 per share, compared to a net loss of $32.2 million, or $0.56 per share for the third quarter of 2024. For the nine months ended...
More Omeros Corporation News

Company Profile

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Head office United States
CEO Gregory Demopulos
Employees 202
Founded 1994
Website www.omeros.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today